Print

NewLink Genetics Announces an Investigator Initiated Phase 2 Study of Sipuleucel-T Plus Indoximod in the Treatment of Certain Men With Advanced Prostate Cancer  
9/21/2012 9:31:38 AM

AMES, Iowa, Sept. 21, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it will begin an investigator initiated, randomized, double blind placebo controlled Phase 2 study entitled "Phase II Study of sipuleucel-T (PROVENGE®) plus indoximod (D-1MT/NLG8189) in the treatment of patients with asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer." This study is done in collaboration with Dendreon Corporation (Nasdaq:DNDN) and the Masonic Cancer Center, University of Minnesota.